Vir Biotechnology doses first patient in Phase I VIR-5500 trial

​Vir Biotechnology has dosed the first patient in one of three expansion cohorts in its ongoing Phase I clinical trial of VIR-5500 for metastatic prostate cancer.

The post Vir Biotechnology doses first patient in Phase I VIR-5500 trial appeared first on Hospital Management.

 

Back to the Featured Stories

Featured Stories

J&J reports 12-month data for Varipulse PFA platform
MSD, Daiichi Sankyo’s ifinatamab deruxtecan receives FDA priority
Zebra Technologies and Aiva Health team up on nurse solutions
FDA issues complete response letter to Replimune’s RP1 for melanoma
BioNTech and DualityBio report positive data for trastuzumab pamirtecan

Connect with us

Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.

Contact Us